ArticleIJID regions2026
Prevalence and antimicrobial resistance trends of ESKAPEE pathogens in clinical isolates from Hyderabad, Pakistan: a cross-sectional study.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Antimicrobial resistance is a major global health threat that limits treatment options and increases morbidity and mortality. ESKAPEE pathogens are prioritized by the World Health Organization and the Centers for Disease Control and Prevention because of their role in nosocomial infections and their ability to evade antimicrobials. This study aimed to determine the prevalence and antimicrobial resistance patterns of ESKAPEE pathogens in Hyderabad, Pakistan. Methods: A cross-sectional study was conducted from August 2023 to August 2024 at the University of Sindh. A total of 1072 clinical specimens were processed for bacterial isolation, identification, and antimicrobial susceptibility testing following Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines. Isolates were classified as multidrug-resistant, extensively drug-resistant, or possible pandrug-resistant using the Magiorakos et al. criteria and the Centers for Disease Control and Prevention/Infectious Diseases Society of America definitions. Results: Among positive cultures, ESKAPEE pathogens accounted for 82.1% of isolates. Conclusion: The high burden of multidrug-resistant and extensively drug-resistant ESKAPEE pathogens highlights the urgent need for strengthened antimicrobial stewardship, continuous surveillance, and rigorous infection-control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.